Is Nektar Therapeutics overvalued?

Nektar Therapeutics (NKTR) — key valuation metrics and fundamentals.

No verdict

Price

$73.02

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$2.09B

Dividend yield

0.0%

Return on equity

-87.0%

Sector

Healthcare

Fair value compares NKTR's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks